Molecure S.A. (WSE:MOC)
Poland · Delayed Price · Currency is PLN 7.04
-0.18 (-2.49%)
Sep 25, 2026, 12:58 PM CET
Molecure Earnings Call Transcripts
Fiscal Year 2024
-
Two main clinical programs advanced, with QATD-01 (sarcoidosis) and QATD-02 (solid tumors) progressing in enrollment and dose escalation, respectively. Financials show reduced costs and stable capital, with ongoing efforts to secure partnerships and grants to fund future development.